Physician profile
Yan Zhang
NPI 1053370395
$3,223.01
in general payments reported to CMS, 2019-2025
29 companies · $630 in 2025
The $630 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $169 · 2020: $36.66 · 2021: $1,093 · 2022: $221 · 2023: $256 · 2024: $817 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,703.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Banner Life Sciences, LLC | $900.00 | 2021 | |
| Alexion Pharmaceuticals, INC. | $344.08 | 2022-2025 | Ultomiris, Soliris |
| Abbvie INC. | $332.33 | 2022-2025 | Qulipta, Ubrelvy |
| Genentech USA, INC. | $191.79 | 2024 | Ocrevus, Ocrevus Zunovo |
| Amgen INC. | $174.15 | 2022-2025 | Uplizna |
| Harmony Biosciences LLC | $131.51 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $130.64 | 2019 | |
| Genzyme Corporation | $124.99 | 2021 | |
| Ucb, INC. | $124.81 | 2023-2024 | Briviact, Fintepla |
| Argenx US, INC. | $91.11 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Novartis Pharmaceuticals Corporation | $77.82 | 2023-2024 | |
| Pfizer INC. | $71.77 | 2023-2025 | |
| Neurelis, INC. | $57.76 | 2023-2025 | Valtoco |
| Becton, Dickinson and Company | $53.26 | 2021-2022 | |
| Tg Therapeutics, INC. | $47.51 | 2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $44.12 | 2023 | Xeomin |
| Biogen, INC. | $42.56 | 2023-2024 | Tysabri, Vumerity |
| Emd Serono, INC. | $36.66 | 2020 | |
| Sk Life Science, INC. | $34.64 | 2024 | |
| Sequel Med Tech, LLC | $29.10 | 2025 | Twiist |
| Sumitomo Pharma America, INC. | $28.68 | 2024 | Aptiom |
| Grifols USA, LLC | $25.95 | 2024 | Gamunex-C |
| Acorda Therapeutics, INC | $22.81 | 2024 | Ampyra |
| Tandem Diabetes Care, INC. | $21.71 | 2019 | |
| Clarus Therapeutics INC. | $20.63 | 2021 | |
| Allergan, INC. | $16.90 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.59 | 2021 | |
| Grt US Holding, INC. | $15.14 | 2022 | |
| Mannkind Corporation | $14.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yan Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.